Insider · CIK 0001706176

Chevallard Daniel R.

Reports to the SEC for 3 companies · SOLANA BEACH, CA

sec.gov

Transactions

Companies

Filings

CIK

0001706176

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-03-27	LENZLENZ Therapeutics, Inc.P Purchase	Chief Financial Officer	PPurchase	+7,500 sh	$8.57	+$64.3K	12,886
2026-01-02	LENZLENZ Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+84.2K sh	—	—	84,200
2026-01-02	LENZLENZ Therapeutics, Inc. · Restricted Stock UnitA Award	Chief Financial Officer	AAward	+14K sh	—	—	14,000
2025-11-07	LENZLENZ Therapeutics, Inc.P Purchase	Chief Financial Officer	PPurchase	+20 sh	$22.71	+$454.2	3,208
2025-11-07	LENZLENZ Therapeutics, Inc.P Purchase	Chief Financial Officer	PPurchase	+2,178 sh	$22.76	+$49.6K	5,386
2025-01-09	LENZLENZ Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+70.4K sh	—	—	70,444
2024-05-14	LENZLENZ Therapeutics, Inc.P Purchase	Chief Financial Officer	PPurchase	+3,188 sh	$15.68	+$50K	3,188
2024-03-21	LENZLENZ Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+200K sh	—	—	200,000
2024-03-12	VIRXViracta Therapeutics, Inc. · Stock Option (Right to Buy)A Award	CFO and COO	AAward	+200K sh	—	—	200,000
2024-02-27	VIRXViracta Therapeutics, Inc.S Sale	CFO and COO	SSale	−3,405 sh	$0.73	−$2,493.141	102,306
2024-02-25	VIRXViracta Therapeutics, Inc.M Exercise/Conversion	CFO and COO	MExercise/Conversion	+6,889 sh	—	—	105,711
2024-02-25	VIRXViracta Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	CFO and COO	MExercise/Conversion	−6,889 sh	—	—	34,444
2023-11-28	VIRXViracta Therapeutics, Inc.S Sale	CFO and COO	SSale	−3,720 sh	$0.50	−$1,860	98,822
2023-11-25	VIRXViracta Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	CFO and COO	MExercise/Conversion	−6,889 sh	—	—	41,333
2023-11-25	VIRXViracta Therapeutics, Inc.M Exercise/Conversion	CFO and COO	MExercise/Conversion	+6,889 sh	—	—	102,542
2023-08-28	VIRXViracta Therapeutics, Inc.S Sale	CFO and COO	SSale	−3,512 sh	$1.45	−$5,092.4	95,653
2023-08-25	VIRXViracta Therapeutics, Inc.M Exercise/Conversion	CFO and COO	MExercise/Conversion	+6,888 sh	—	—	99,165
2023-08-25	VIRXViracta Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	CFO and COO	MExercise/Conversion	−6,888 sh	—	—	48,222
2023-05-25	VIRXViracta Therapeutics, Inc.S Sale	CFO and COO	SSale	−3,635 sh	$1.42	−$5,160.246	92,277
2023-05-25	VIRXViracta Therapeutics, Inc.M Exercise/Conversion	CFO and COO	MExercise/Conversion	+6,889 sh	—	—	95,912
2023-05-25	VIRXViracta Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	CFO and COO	MExercise/Conversion	−6,889 sh	—	—	55,110
2023-03-16	VIRXViracta Therapeutics, Inc. · Stock Option (Right to Buy)A Award	CFO and COO	AAward	+200K sh	—	—	200,000
2023-02-27	VIRXViracta Therapeutics, Inc.S Sale	CFO and COO	SSale	−3,599 sh	$1.68	−$6,050.639	89,023
2023-02-25	VIRXViracta Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	CFO and COO	MExercise/Conversion	−6,889 sh	—	—	61,999
2023-02-25	VIRXViracta Therapeutics, Inc.M Exercise/Conversion	CFO and COO	MExercise/Conversion	+6,889 sh	—	—	92,622
2022-11-28	VIRXViracta Therapeutics, Inc.S Sale	CFO and COO	SSale	−3,532 sh	$2.72	−$9,605.627	85,733
2022-11-25	VIRXViracta Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	CFO and COO	MExercise/Conversion	−6,889 sh	—	—	68,888
2022-11-25	VIRXViracta Therapeutics, Inc.M Exercise/Conversion	CFO and COO	MExercise/Conversion	+6,889 sh	—	—	89,265
2022-08-26	VIRXViracta Therapeutics, Inc.S Sale	CFO and COO	SSale	−3,655 sh	$4.02	−$14.7K	82,376
2022-08-25	VIRXViracta Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	CFO and COO	MExercise/Conversion	−6,889 sh	—	—	75,777
2022-08-25	VIRXViracta Therapeutics, Inc.M Exercise/Conversion	CFO and COO	MExercise/Conversion	+6,889 sh	—	—	86,031
2022-05-26	VIRXViracta Therapeutics, Inc.S Sale	CFO and COO	SSale	−3,596 sh	$1.90	−$6,836.356	79,142
2022-05-25	VIRXViracta Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	CFO and COO	MExercise/Conversion	−6,889 sh	—	—	82,666
2022-05-25	VIRXViracta Therapeutics, Inc.M Exercise/Conversion	CFO and COO	MExercise/Conversion	+6,889 sh	—	—	82,738
2022-03-17	VIRXViracta Therapeutics, Inc. · Stock Option (Right to Buy)A Award	CFO and COO	AAward	+195K sh	—	—	195,000
2022-02-28	VIRXViracta Therapeutics, Inc.S Sale	CFO and COO	SSale	−3,998 sh	$2.78	−$11.1K	75,849
2022-02-25	VIRXViracta Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	CFO and COO	MExercise/Conversion	−6,889 sh	—	—	89,555
2022-02-25	VIRXViracta Therapeutics, Inc.M Exercise/Conversion	CFO and COO	MExercise/Conversion	+6,889 sh	—	—	79,847
2021-11-29	VIRXViracta Therapeutics, Inc.S Sale	CFO and COO	SSale	−4,325 sh	$4.82	−$20.8K	72,958
2021-11-26	VIRXViracta Therapeutics, Inc.S Sale	CFO and COO	SSale	−3,254 sh	$4.80	−$15.6K	77,283
2021-11-25	VIRXViracta Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	CFO and COO	MExercise/Conversion	−13.8K sh	—	—	96,444
2021-11-25	VIRXViracta Therapeutics, Inc.M Exercise/Conversion	CFO and COO	MExercise/Conversion	+13.8K sh	—	—	80,537
2021-09-28	VIRXViracta Therapeutics, Inc.M Exercise/Conversion	CFO and COO	MExercise/Conversion	+10K sh	$0.90	+$9,000	66,760
2021-09-28	VIRXViracta Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	CFO and COO	MExercise/Conversion	−10K sh	—	—	88,817
2021-05-28	VIRXViracta Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	CFO and COO	MExercise/Conversion	−12K sh	—	—	98,817
2021-05-28	VIRXViracta Therapeutics, Inc.M Exercise/Conversion	CFO and COO	MExercise/Conversion	+12K sh	$0.90	+$10.8K	56,760
2021-03-26	VIRXViracta Therapeutics, Inc. · Stock Option (Right to Buy)A Award	CFO and COO	AAward	+78.9K sh	—	—	78,912
2019-07-01	Regulus Therapeutics Inc.S Sale	Chief Financial Officer	SSale	−2,669 sh	$1.31	−$3,500.394	77,870
2019-05-15	Regulus Therapeutics Inc.S Sale	Chief Financial Officer	SSale	−10K sh	$1.41	−$14.1K	80,539
2019-05-14	Regulus Therapeutics Inc.Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+8,000 sh	—	—	7,500

Recent filings

Accepted (ET)
Mar 304
Chevallard Daniel R.0001706176-26-000004
SEC(opens sec.gov)
Jan 64
Chevallard Daniel R.0001706176-26-000002
SEC(opens sec.gov)
Nov 74
Chevallard Daniel R.0001815776-25-000072
SEC(opens sec.gov)
Jan 134
Chevallard Daniel R.0001815776-25-000005
SEC(opens sec.gov)
May 154
Chevallard Daniel R.0001815776-24-000046
SEC(opens sec.gov)
Mar 254
Chevallard Daniel R.0001815776-24-000023
SEC(opens sec.gov)
Mar 134
Chevallard Daniel R.0001209191-24-004825
SEC(opens sec.gov)
Feb 274
Chevallard Daniel R.0001209191-24-004037
SEC(opens sec.gov)
Nov 284
Chevallard Daniel R.0001209191-23-056842
SEC(opens sec.gov)
Aug 294
Chevallard Daniel R.0001209191-23-047665
SEC(opens sec.gov)
May 264
Chevallard Daniel R.0001209191-23-032707
SEC(opens sec.gov)

Companies

Address

C/O LENZ THERAPEUTICS, INC. 201 LOMAS SANTA FE DRIVE, SUITE 300

SOLANA BEACH, CA, 92075